Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer

被引：2
|
作者：
Chiorean, E. Gabriela
Whiting, Scott
Binder, Gary
Dranitsaris, George
Manax, Victoria
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Celgene Corp, Summit, NJ USA
[3] Augmentium Pharma Consulting, Toronto, ON, Canada
[4] Celgene, Summit, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.353
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
353
引用
收藏
页数：1
相关论文
共 50 条
  • [21] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [22] Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
    Wenjie Liu
    Yuting Fang
    Chao Zhang
    Midan Xiang
    Lijuan Qi
    Aijiang Su
    Yongkun Sun
    BMC Gastroenterology, 25 (1)
  • [23] Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in locally advanced/borderline resectable pancreatic cancer patients.
    Ingram, Myles
    Lauren, Brianna N.
    Pumpalova, Yoanna S.
    Manji, Gulam Abbas
    Bates, Susan Elaine
    Hur, Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
    Kamata, Ken
    Imai, Hajime
    Matsumoto, Hisakazu
    Yamashita, Yukitaka
    Kato, Takao
    Nishi, Katsuhisa
    Omoto, Shunsuke
    Minaga, Kosuke
    Yamao, Kentaro
    Hyodo, Tomoko
    Im, Sung-Woon
    Hara, Akane
    Yoshikawa, Tomoe
    Ishikawa, Rei
    Okamoto, Ayana
    Yamazaki, Tomohiro
    Nakai, Atsushi
    Ueshima, Kazuomi
    Chiba, Yasutaka
    Takenaka, Mamoru
    Watanabe, Tomohiro
    Kitano, Masayuki
    Kudo, Masatoshi
    JGH OPEN, 2023, 7 (09): : 659 - 666
  • [25] The retrospective analysis of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer
    Ueno, M.
    Kobayashi, S.
    Ohkawa, S.
    Tezuka, S.
    Moriya, S.
    Morimoto, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 67 - 67
  • [26] Reinitiating nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Borazanci, Erkut
    Schroeder, Katy
    Jameson, Gayle S.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [27] Gemcitabine plus nab-paclitaxel in Japan
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Ookawa, Kazuyoshi
    Takahashi, Hidenori
    Teshima, Teruki
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    FUTURE ONCOLOGY, 2022, 18 (21) : 2643 - 2654
  • [29] Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer
    Gharaibeh, Mahdi
    McBride, Ali
    Bootman, J. Lyle
    Patel, Hitendra
    Abraham, Ivo
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (04) : 345 - 352
  • [30] Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
    Dorman, Klara
    Boeck, Stefan
    Caca, Karel
    Reichert, Maximilian
    Ettrich, Thomas J.
    Oettle, Helmut
    Waidmann, Oliver
    Modest, Dominik P.
    Mueller, Lothar
    Michl, Patrick
    Kanzler, Stephan
    Pink, Daniel
    Reinacher-Schick, Anke
    Geissler, Michael
    Pelz, Henning
    Kunzmann, Volker
    Held, Swantje
    Schichtl, Thomas
    Heinemann, Volker
    Kullmann, Frank
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (10): : 935 - 943
12345